Clear All
731 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9214 Bevacizumab Avastin 10 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Feb 26, 2004 Dec 31, 2004 No Longer Used
J9226 Histrelin Acetate Supprelin LA 50 mg Hormonal Therapy GnRH Agonist No 2004 Jan 1, 2008 In Use
J1675 Histrelin Acetate Supprelin LA, Vantas 10 mcg Hormonal Therapy GnRH Agonist No 2004 Jan 1, 2006 In Use
C9215 Cetuximab Erbitux 10 mg Immunotherapy Monoclonal Antibody EGFR No 2004 Feb 12, 2004 Dec 31, 2004 No Longer Used
J2425 Palifermin Kepivance 50 mcg Ancillary Therapy Epithelial Growth Factor Keratinocyte Growth Factor/rHuKGF No 2004 Jan 1, 2006 In Use
J9055 Cetuximab Erbitux 10 mg Immunotherapy Monoclonal Antibody EGFR No 2004 Jan 1, 2005 In Use
J9025 Azacitidine Vidaza 1 mg Chemotherapy Antimetabolite Pyrimidine Analog No 2004 Jan 1, 2006 In Use
C9213 Pemetrexed Alimta 10 mg Chemotherapy Antimetabolite Folic Acid Analog No 2004 Feb 4, 2004 Dec 31, 2004 No Longer Used
Q2024 Bevacizumab Avastin 0.25 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Oct 1, 2009 Dec 31, 2009 No Longer Used
J9225 Histrelin Acetate Vantas 50 mg Hormonal Therapy GnRH Agonist No 2004 Jan 1, 2008 In Use
C9257 Bevacizumab Avastin 0.25 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Jan 1, 2010 In Use
J8501 Aprepitant Emend 5 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 Jan 1, 2005 In Use
NA Aprepitant Emend 40 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
A9545 Tositumomab Bexxar, Iodine i-131 Tositumomab, therapeutic Per treatment dose Immunotherapy, Radiopharmaceutical Radioimmunotherapy CD20 No 2003 2014 Jan 1, 2006 In Use
NA Aprepitant Emend 80 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
A9534 Tositumomab Bexxar, Iodine i-131 Tositumomab, therapeutic per MC Immunotherapy, Radiopharmaceutical Radioimmunotherapy CD20 No 2003 2014 Jul 1, 2003 In Use
J9041 Bortezomib Velcade 0.1 mg Chemotherapy Proteasome Inhibitor 26S No 2003 Jan 1, 2005 In Use
NA Aprepitant Emend 125 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
S0165 Abarelix Plenaxis 100 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan 1, 2005 No Longer Used
J0128 Abarelix Plenaxis 10 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan 1, 2005 No Longer Used
C9216 Abarelix Plenaxis 10 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan 1, 2005 No Longer Used
C9210 Palonosetron Aloxi 25 mcg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2003 Jan 1, 2004 Dec 31, 2004 No Longer Used
S0115 Bortezomib Velcade 3.5 mg Chemotherapy Proteasome Inhibitor 26S No 2003 Jan 1, 2004 Dec 31, 2004 No Longer Used
J2469 Palonosetron Aloxi 25 mcg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2003 Jan 1, 2005 In Use
J2506 Pegfilgratim (ex Biosimilars) Neulasta 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2002 Jan 26, 2022 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.